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Objective: Neuromelanin loss of substantia nigra (SN) can be visualized as a T1 signal reduction on T1-weighted high-
resolution imaging. We investigated whether volumetric analysis of T1 hyperintensity for SN could be used to differentiate 
between Parkinson’s disease dementia (PDD), Alzheimer’s disease (AD) and age-matched controls.
Materials and Methods: This retrospective study enrolled 10 patients with PDD, 18 patients with AD, and 13 age-matched 
healthy elderly controls. MR imaging was performed at 3 tesla. To measure the T1 hyperintense area of SN, we obtained an 
axial thin section high-resolution T1-weighted fast spin echo sequence. The volumes of interest for the T1 hyperintense SN 
were drawn onto heavily T1-weighted FSE sequences through midbrain level, using the MIPAV software. The measurement 
differences were tested using the Kruskal-Wallis test followed by a post hoc comparison. 
Results: A comparison of the three groups showed significant differences in terms of volume of T1 hyperintensity (p < 
0.001, Bonferroni corrected). The volume of T1 hyperintensity was significantly lower in PDD than in AD and normal 
controls (p < 0.005, Bonferroni corrected). However, the volume of T1 hyperintensity was not different between AD and 
normal controls (p = 0.136, Bonferroni corrected). 
Conclusion: The volumetric measurement of the T1 hyperintensity of SN can be an imaging marker for evaluating neuromelanin 
loss in neurodegenerative diseases and a differential in PDD and AD cases.
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INTRODUCTION
In human brain, dopamine metabolism produces 
neuromelanin, a dark pigment that is a by-product in 
substantia nigra (SN) and gives a dark color to the 
structure. In Parkinson’s disease (PD), along with a 
dopaminergic neuronal loss, neuromelanin levels are also 
decreased. This is because neuromelanin is mostly within 
the dopaminergic cells in an intracellular form although a 
smaller portion becomes extracellular when released from 
dying cells (1, 2).
Neuromelanin has an important role in protecting against 
oxidative stress-induced neuronal damage by toxic metals; 
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data of T1 hyperintensity in SN from PDD, AD and healthy 
subjects. 
MATERIALS AND METHODS
Study Subjects
This retrospective study included 10 patients with PDD, 
18 patients with AD and 13 age-matched healthy controls 
(Table 1). The patients with PDD and AD were recruited 
from the dementia center of our hospital, between August 
2006 and July 2010. All patients were diagnosed based 
on information obtained from an extensive clinical history 
and neurological examination. All PDD patients were 
diagnosed according to the Brain Clinical Diagnosis Criteria 
from Parkinson’s Disease Society in United Kingdom (13), 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) and the Emre et al. (14) PDD 
criteria. The diagnosis of dementia and probable AD was 
based on the DSM-IV criteria, and criteria recommended by 
the National Institute of Neurological and Communicative 
Disorders and Stroke, and the Alzheimer Patients and 
Related Disorders Association (15). The subjects who 
fulfilled the criteria for dementia with Lewy bodies (DLB) 
were excluded in this study (16).
Thirteen age-matched control subjects were selected 
from a consecutive series of patients, referred for the 
same MR imaging protocol as patients with PDD and AD, 
as part of a medical checkup between June 2007 and 
August 2011. The following criteria were used for inclusion 
of the control subjects in the study: no clinical evidence 
of neuropsychiatric disorders and no apparent abnormal 
findings on MRI scans. We excluded patients with a history 
of neurological disease, malignancy, stroke, or brain surgery. 
Indications for MRI scans in the controls were headaches (n 
= 1), dizziness or vertigo (n = 2), and health screening (n = 
10). 
All subjects undertook a standard battery of 
it protects by chelating the metals in the cell by forming 
stable complexes (3). In 2006, Sasaki et al. (4) first 
demonstrated in-vivo neuromelanin imaging with 3 tesla 
(3T) magnetic resonance imaging (MRI). That pioneering 
study indicated that MRI dark-pigmented SN on pathologic 
specimens show prominent T1 hyperintensity, and that the 
T1 signal of SN is decreased in PD, compared to scans from 
normal volunteers. Additional work has suggested that the 
T1 hyperintensity of SN may be from a paramagnetic T1 
shortening effect (4, 5). Besides the changes seen in PD, 
loss of T1 hyperintensity of SN has also been observed in 
multiple system atrophy (6), progressive supranuclear palsy 
(7), corticobasal degeneration (8), and psychiatric disorders 
such as depression and schizophrenia (9).
Aside from motor-related symptoms, dementia is also 
quite common in PD, occurring in 40% of patients with 
the disease. PD-related dementia (PDD) is characterized 
by executive dysfunction, disordered attention, and 
decreased visuospatial/constructional abilities (10). As 
26% of patients with PDD present with cognitive symptoms 
that overlap those observed in patients with Alzheimer’s 
disease (AD), a differential diagnosis between PDD and AD 
is sometimes difficult especially in the early stages and 
particularly when using neuropsychiatric tests alone (10, 
11). Despite overlapping cognitive symptoms, the major 
pathology of PDD is loss of the neuromelanin-containing 
dopaminergic neurons of SN, while that of AD is not, 
although there is a debate on the role of dopamine in AD 
pathology (12). In addition, neuromelanin depletion in 
PDD on MRI has not been studied yet while neuromelanin 
depletion has been extensively studied in PD as a whole 
group.
Hence, we hypothesized that the volume of neuromelanin-
induced T1 signal intensity would be decreased in PDD, but 
not in AD and the age-matched controls and the volume 
measurement would differentiate PDD from AD and the 
control subjects. For our study, we evaluated volumetry 
Table 1. Demographic Data
PDD (n = 10) AD (n = 18) Normal (n = 13)
Men:women 7:3 8:10 1:12
Age (years) 71.7 ± 8.0* 73.0 ± 5.8 72.2 ± 10.2
MMSE 21.9 ± 4.0 22.0 ± 4.2 25.0 ± 4.4
Mean duration of dementia, months 3.7 ± 4.7 22.0 ± 18.0 N/A
Mean duration before PDD, months 59.2 ± 44.0 N/A N/A
Hoehn-Yahr staging 2.25 ± 0.72† N/A N/A
*Values are mean ± SD, †As value at diagnosis of PDD. AD = Alzheimer’s disease, MMSE = mini-mental state examination, N/A = not 
applicable, PDD = Parkinson’s disease dementia
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neuropsychological tests, including an assessment of global 
cognitive impairment using the scales for the mini-mental 
state examination and of global functional impairment using 
the Clinical Dementia Rating. An expert neuroradiologist 
with 17-years of experiences reviewed the MR images, in 
order to rule out any major neuropathology including a 
tumor, stroke or inflammatory/infective diseases. 
Our Institutional Review Board approved the study, and 
written informed consent from the study subjects was 
waived. 
MR Image Acquisition
All patients undertook MR imaging using a 3T unit 
(Signa HDxT; GE Healthcare, Milwaukee, WI, USA) with 
an 8-channel head coil. The routine MR imaging protocol 
included the following sequences: 1) axial and sagittal T1-
weighted inversion-recovery (repetition time [TR]/echo 
time [TE]/inversion time [TI], 2468/12/920 ms; section 
thickness, 5 mm; matrix, 512 x 224); 2) axial T2-weighted 
fast-spin echo (FSE) (TR/effective TE, 4000/106 ms; 
section thickness, 5 mm; matrix, 384 x 384); 3) axial fluid-
attenuated inversion-recovery (TR/TE/TI, 11000/105/2600 
ms; sectional thickness, 5 mm; matrix 384 x 224); 4) axial 
T2-weighted gradient-echo (GRE) (TR/TE, 550/17 ms; section 
thickness, 5 mm; matrix, 384 x 224; flip angle, 15°); and 5) 
T1-weighted volumetric spoiled gradient recalled-echo (TR/
TE, 7.3/2.7 ms; section thickness, 1.5 mm; matrix, 256 x 
256; flip angle, 13°). The field of view (FOV) was 230 x 230 
mm. 
To visualize neuromelanin of SN, we obtained a thin 
section T1-weighted FSE sequence for upper brain stem 
with the following parameters: TR/TE, 600/14 ms; number 
of slices, 10; section thickness, 2.5 mm with intersection 
gap of 1 mm; matrix, 512 x 320; FOV, 220 x 220 mm; 
the number of acquisition, 4. The acquisition time was 3 
minutes 40 seconds. The sequence was obtained in the 
oblique axial planes perpendicular to the 4th ventricle floor 
with coverage from the posterior commissure to the inferior 
border of the pons. We made sure that one section was 
located at the inferior edge of the inferior colliculi, for the 
best visualization of SN.
MR Image Analysis 
The volume of T1 hyperintensity was measured by tracing 
volumes of interest (VOIs) on each slice of T1-weighted 
FSE sequences where the T1 hyperintensity could be seen. 
VOIs’ contours were defined semi-automatically using the 
level-set VOI tool of Medical Imaging Processing, Analysis 
and Visualization (MIPAV) (http://mipav.cit.nih.gov/). In 
this method, MIPAV software first analyzes the intensity 
values and uses the results from its level-set algorithm to 
determine the probable boundary of the T1 hyperintensity 
of SN, and then generates a contour. The total volume of 
neuromelanin was calculated by adding all the VOIs of 
the T1 hyperintensity of SN for each patient (Fig. 1). The 
window level and width was set as the signal intensity of 
the decussation of the superior cerebellar peduncle (DSCP) 
and 70% of the signal intensity of DSCP in the slice of SN. 
A National Institute of Health lookup table MIPAV software 
was applied to all the images. An experienced rater with 
four-year-experience of neuroimaging processing performed 
the entire imaging analysis under the supervision of a 
neuroradiologist. Imaging analysis was performed in a 
blinded manner for the diagnosis of subjects. 
For normalization of the signal intensity, we also defined 
region of interest of 30 mm3 symmetrically in the ventral 
tegmentum located in the anterolateral areas of aqueduct 
as background. We calculated the normalized signal 
intensity of SNs by dividing their signal intensity by that 
of background area, i.e., the tegmentum of midbrain, then 
multiplied by 100. 
To assess measurement reliabilities, we randomly selected 
the MR images of 26 subjects (two-thirds of cases in the 
study group). For those subjects, the rater repeated the 
measurement of the T1 hyperintensity volume at least 2 
weeks apart. For inter-observer reliability, another rater 
Fig. 1. VOI placement of neuromelanin-sensitive T1 
hyperintensity volume of SN by level-set VOI tool. Dotted 
lined area is T1 hyperintense area of right SN in control subject. SN = 
substantia nigra, VOI = volume of interest
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of a three-year experience of neuroimaging processing 
independently measured and recorded the T1 hyperintensity 
volume of SN. 
Statistical Analysis
A statistical analysis was performed by using the 
Statistical Package for the Social Sciences (version 17.0 for 
Windows; SPSS Inc., Chicago, IL, USA) and MedCalc (version 
15.2.2, Mariakerke, Belgium). P < 0.05 was considered 
as statistically significant. Before performing individual 
analyses, the distribution of data sets was checked for 
normality. To compare the clinical features between AD 
and PDD, we used the Mann-Whitney U test for continuous 
variables. The Kruskal-Wallis test was used to evaluate 
differences in the neuromelanin volume of SN and the 
signal intensities of neuromelanin of SN among all groups, 
followed by a post hoc comparison. The correlation between 
age and MR imaging measurement was assessed with 
the Spearman correlation coefficient. The inter-observer 
and intra-observer agreement between the 2 raters were 
assessed with the intraclass correlation coefficient.
RESULTS
Three groups showed significant differences in terms 
of the volume of T1 hyperintensity (p < 0.001). The mean 
volume of T1 hyperintensity was significantly lower in PDD 
than in AD and normal controls (64.36 ± 28.21 mm3 vs. 
160.59 ± 65.26 mm3 vs. 232.30 ± 110.79 mm3, respectively) 
(p < 0.005, Bonferroni corrected) (Fig. 2). However, the 
volume of T1 hyperintensity was not different between AD 
and the normal controls (p = 0.136, Bonferroni corrected) 
(Fig. 3). On the other hand, the mean normalized signal 
intensity of T1 hyperintensity was not statistically different 
among the three groups (p = 0.118). Nevertheless, the mean 
normalized SI of the SN VOI tended to be lower in PDD than 
in AD and the normal controls (1005.93 ± 76.77 vs. 1044.59 
± 119.18 vs. 1077.91 ± 73.24, respectively) (Fig. 4).
In normal healthy controls, age did not correlate with 
either the volume or the mean signal intensity of the T1 
shortening of SN (p = 0.640 and 0.469). 
Regarding the inter-observer agreement, the intraclass 
correlation coefficient for the T1 hyperintensity volume 
was 0.888 (95% confidence interval: 0.810–0.942, p < 
0.001). In terms of the intra-observer agreement, the mean 
intraclass correlation coefficient value between the first 
and second measurement of the same data was 0.941 (95% 
confidence interval: 0.854–0.969, p < 0.001).
DISCUSSION
The results of our study indicated that the volume of 
the T1 hyperintensity of SN was markedly decreased in 
PDD, but not in AD and control subjects. Nevertheless, AD 
Fig. 2. Differences for SN between PDD, AD and control subjects in neuromelanin-sensitive T1-weighted imaging. 
Axial T1-weighted fast spin-echo (TR/TE, 600/14 ms; section thickness, 2.5 mm) MR images reveal neuromelanin containing SN in red color. 
Compared with control subject (A), mean T1 hyperintensity of SN seems to be reduced with preserved volume in patient with AD (B). Mean 
signal intensity and volume of T1 hyperintensity of SN is decreased in patient with PDD (C). AD = Alzheimer’s disease, MR = magnetic resonance, 
PDD = Parkinson’s disease dementia, SN = substantia nigra, TE = echo time, TR = repetition time
A B C
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patients tended to show a mild decrease in the volume of 
T1 hyperintensity, as compared with the control subjects. 
Although T1 hyperintensity of SN has been a hot topic in 
PD studies, T1 hyperintensity of SN has not been studied 
yet in patients with PDD. Decreased volume in the T1 
hyperintensity of SN for the patients with PDD is consistent 
with the findings in previous reports on PD (4, 6, 17-
19). Since the first report (4), there have been several 
reports on reduction in the T1 hyperintensity in various 
neurodegenerative diseases. In subsequent studies, the area 
or volume of the T1 hyperintensity of SN were reportedly 
decreased in PD compared with the control subjects (17, 
18, 20). In addition, the degree of the T1 hyperintensity 
differed between early and late stage of PD (7). 
Sasaki et al. (4, 5) suggested that T1 hyperintensity at 
the level of the midbrain is for SN neuromelanin-pigmented 
cells, which are known as the pars compacta of SN. From 
a study of pathologic correlations, the T1 hyperintensity 
of SN is consistent with the neuromelanin-containing area 
(16). Neuromelanin protects neurons against the toxic 
catecholamine accumulation and oxidative stress by binding 
with metals such as iron, zinc, copper and manganese 
(3, 21). T1 hyperintensity of neuromelanin is mainly 
attributed to its paramagnetic property. When combining 
with metals such as iron and copper, neuromelanin shows 
paramagnetic contrast (22). Magnetization transfer effect 
due to multislice FSE sequence augments T1 hyperintensity 
by suppressing surrounding tissue signal intensity (21, 23). 
Although, there were debates on whether the boundary of 
the T1 hyperintensity or T2 hypointensity represents exactly 
the boundary of the pars compacta of SN, recent studies 
showed that T1 hyperintense area was located posterior to 
T2 hypointense area, at the pars compacta by obtaining 
susceptibility weighted imaging (SWI) and T1-weighted 
image at the same time (24). The broader T1 hyperintense 
area of the medial part of SN in our subject may be part of 
the ventral tegmental area, where dopaminergic neurons 
reside (5). 
For AD, as another common neurodegenerative disease, 
only one recent report observed the decreased T1 
hyperintensity in AD (19); however, to the best of our 
knowledge, our study is the first report that has compared 
AD, PDD and healthy controls in terms of the volume of 
the T1 hyperintensity of SN. In pathology and imaging 
studies, degeneration of SN is reported in patients with AD 
(12, 19). However, it was not clear whether SN has only 
secondary degenerative change or there is clear cell loss 
in AD patients. Our results suggest that there is at least 
a minor degree of cell loss in AD. In the step of patient 
inclusion, we meticulously excluded patients who fulfilled 
Fig. 3. Boxplot of T1 hyperintensity volume of PDD, AD and 
control subjects. Line across box represents median value. Box ends 
represent first and third quartiles. End points of each graph represent 
smallest and largest values. Median volume of T1 hyperintensity of SN 
is lowest in PDD group of patients compared with patients with AD 
and control subjects. On other hand, volume of T1 hyperintensity is 
partly overlapped between patients with AD and control subjects. AD 
= Alzheimer’s disease, PDD = Parkinson’s disease dementia
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DLB (16). Nevertheless, without an autopsy confirmation, 
we cannot exclude the possibility of Lewy body pathology 
in our patients with AD. In addition, pathologic change 
of nigrostriatal pathway with Lewy bodies and alpha-
synucleinopathy, which is characteristic of DLB, has been 
also reported in about 50% of AD patients and 30% of aged 
healthy subjects (12). 
The signal intensity of neuromelanin showed no 
differences between the three groups. A decreased volume 
but preserved signal intensity of SN in PDD suggests that 
the main pathology is not lower neuromelanin content 
of each neuron, but a decrease in number of melanin-
containing neurons in SN. PDD is an eventual result of PD, 
hence, our finding is also supported by previous reports 
that neuronal depletion of SN is the key finding in PD, 
although neuromelanin synthesis is reportedly reduced (1, 
25).
In this study, there was no correlation between age 
and the volume of the T1 hyperintensity of SN in normal 
subjects. Our result was in accord with the previously 
published result (17). Our finding suggests that the volume 
change of the T1 hyperintensity is not merely an age-related 
change but a pathologic change due to neuromelanin-
containing dopaminergic cell loss. 
Compared with the AD and control subjects, PDD 
showed profoundly reduced volume of T1 hyperintensity 
of SN. Obtaining a differential diagnosis of PDD and AD is 
sometimes difficult based on symptoms and clinical tests 
alone (11). Hence, more objective tests, such as the T1 
hyperintensity volume measures, may be helpful in early 
diagnosis of PDD vs. AD. In addition to PDD and AD, several 
neurodegenerative disorders such as PSP and CBD can show 
both clinical symptoms of dementia and imaging findings 
of the reduced T1 hyperintensity of SN (7, 26). PSP and 
CBD, however, have characteristic clinical features and are 
relatively rare in prevalence. Future study involving patients 
with earlier stages of PDD, AD, as well as PSP and CBD will 
be helpful in this regard. 
Unlike our study, most previous MR imaging studies of 
SN in PD and PDD have used proton-density weighted 
imaging, and GRE and SWI (27-30). Most of them presumed 
that iron accumulation in the SN can produce the T2* 
shortening and that iron-sensitive imaging can mirror 
the change of SN by visualizing the iron accumulation 
in the SN or by visualizing the iron-depleted area of the 
dopaminergic cell-containing nigrosome (30, 31). However, 
these studies have often shown conflicting results as 
the iron accumulated area did not correspond to the SN 
boundary on the pathologic specimens (5, 31). Especially, 
detection of the loss of the nigrosome on the T2*-weighted 
imaging or iron-sensitive imaging, i.e., finding darkness 
from brightness of nigrosome, can be bothersome because 
it requires human visual perception in a less intuitive 
way. Thus, the neuromelanin sequence may be more 
accurate in determining the pathology of SN than iron-
sensitive imaging, because of the direct correlation of the 
neuromelanin sequence with neuromelanin-containing cells, 
which is the pathologic target of PDD. 
In our analysis, volumetric measurements of T1 
hyperintense SN showed high inter-rater and intra-rater 
agreement. Because of the high reliability, volumetry of T1 
hyperintense SN could be a helpful imaging marker for the 
evaluation of PDD and AD. 
Our study had several limitations. First, our disease 
groups were < 20 subjects each. Second, the SN volumes 
were not normalized to the intracranial volume to control 
for variability in the dimensions of structures across the 
subjects. As such, the effect of general atrophy cannot 
be ruled out. Third, a relatively low signal to noise ratio 
of the neuromelanin-sensitive sequence might induce an 
inhomogeneity of the signal intensity, which might affect 
the results (5). We carefully reviewed signal intensity 
inhomogeneity before the final approval of the MR 
examination of each patient and performed additional 
phantom test for quality control of T1-weighted images to 
minimize the inhomeogeneity effect. To overcome these 
limitations, a larger scale prospective comparison study of 
SWI and the neuromelanin sequence will be necessary in 
the near future. 
In conclusion, the T1 hyperintensity volume of SN was 
significantly lower in patients with PDD, as compared with 
patients with AD and the normal controls. Assessment of 
the volume of neuromelanin T1 hyperintensity of SN may 
be useful to differentiate PDD from other degenerative 
diseases. 
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